ArticleClinical pharmacology and therapeutics2026
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.
Ying Hong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.